# Bevacizumab for Central Retinal Vein Occlusion Study

> **NCT00906685** · PHASE3 · COMPLETED · sponsor: **Anders Kvanta** · enrollment: 60 (actual)

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** Sham bevacizumab injection

## Key facts

- **NCT ID:** NCT00906685
- **Lead sponsor:** Anders Kvanta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906685, "Bevacizumab for Central Retinal Vein Occlusion Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00906685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*